medwireNews: The EMA’s Committee for Medicinal Products for Human Use has adopted an extension to the indication for durvalumab to include patients with extensive-stage small-cell lung cancer.
The PD-L1 inhibitor, in combination with etoposide and carboplatin or cisplatin, is now recommended for the first-line treatment of these patients.
Advertisement
Durvalumab was previously approved in Europe as maintenance therapy for individuals with stage III non-small-cell lung cancer, PD-L1 tumoral expression level of at least 1%, and no progression after platinum-based chemoradiotherapy.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group